Table 4
Cancer Mortality by Primary Site and Age at Death
Michigan Residents, 2020
| Primary Site (ICD-10 Death Site Groupings) |
Total | Less than 50 Years | 50 - 74 Years | 75 Years & Over | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | Age- Adjusted Rate |
Number | Age- Specific Rate |
Number | Age- Specific Rate |
Number | Age- Specific Rate |
|||||
| Gastrointestinal Tract & Digestive System |
5,932 | 44.6 | ±1.1 | 250 | 4.0 | ±0.5 | 3,328 | 105.9 | ±3.5 | 2,354 | 336.4 | ±13.0 |
| Lip, Oral Cavity & Pharynx | 342 | 2.5 | ±0.3 | 18 | 0.3 | ±0.1 | 216 | 6.9 | ±0.9 | 108 | 15.4 | ±2.9 |
| Stomach | 300 | 2.3 | ±0.2 | 16 | 0.3 | ±0.1 | 161 | 5.1 | ±0.8 | 123 | 17.6 | ±3.1 |
| Colon | 1,444 | 11.3 | ±0.5 | 91 | 1.5 | ±0.3 | 691 | 22.0 | ±1.6 | 662 | 94.6 | ±7.1 |
| Rectum | 394 | 3.0 | ±0.3 | 28 | 0.4 | ±0.2 | 236 | 7.5 | ±1.0 | 130 | 18.6 | ±3.2 |
| Pancreas | 1,693 | 12.6 | ±0.6 | 51 | 0.8 | ±0.2 | 945 | 30.1 | ±1.9 | 697 | 99.6 | ±7.3 |
| Other Gastrointestinal Tract & Digestive System |
1,759 | 12.8 | ±0.6 | 46 | 0.7 | ±0.2 | 1,079 | 34.3 | ±2.0 | 634 | 90.6 | ±7.0 |
| Respiratory System & Pleura |
5,393 | 39.5 | ±1.0 | 87 | 1.4 | ±0.3 | 3,152 | 100.3 | ±3.5 | 2,154 | 307.8 | ±12.5 |
| Larynx | 155 | 1.1 | ±0.2 | 1 | * | 102 | 3.2 | ±0.6 | 52 | 7.4 | ±2.0 | |
| Lung & Bronchus | 5,201 | 38.1 | ±1.0 | 80 | 1.3 | ±0.3 | 3,032 | 96.4 | ±3.4 | 2,089 | 298.6 | ±12.3 |
| Other Respiratory | 37 | 0.3 | ±0.1 | 6 | 0.1 | ±0.1 | 18 | 0.6 | ±0.3 | 13 | 1.9 | ±1.0 |
| Bones & Soft Tissue | 207 | 1.7 | ±0.2 | 43 | 0.7 | ±0.2 | 103 | 3.3 | ±0.6 | 61 | 8.7 | ±2.2 |
| Melanoma of Skin | 229 | 1.8 | ±0.2 | 17 | 0.3 | ±0.1 | 122 | 3.9 | ±0.7 | 90 | 12.9 | ±2.7 |
| Breast | 1,432 | 11.3 | ±0.5 | 106 | 1.7 | ±0.3 | 724 | 23.0 | ±1.7 | 602 | 86.0 | ±6.8 |
| Genitourinary Organs | 3,381 | 26.1 | ±0.8 | 120 | 1.9 | ±0.3 | 1,455 | 46.3 | ±2.4 | 1,806 | 258.1 | ±11.5 |
| Cervix Uteri | 112 | 1.0 | ±0.2 | 33 | 0.5 | ±0.2 | 60 | 1.9 | ±0.5 | 19 | 2.7 | ±1.2 |
| Corpus Uteri | 246 | 1.8 | ±0.2 | 10 | 0.2 | ±0.1 | 139 | 4.4 | ±0.7 | 97 | 13.9 | ±2.8 |
| Ovary | 490 | 3.8 | ±0.3 | 37 | 0.6 | ±0.2 | 272 | 8.7 | ±1.0 | 181 | 25.9 | ±3.8 |
| Prostate Gland | 1,099 | 8.5 | ±0.4 | 4 | * | 377 | 12.0 | ±1.2 | 718 | 102.6 | ±7.4 | |
| Other Genital | 339 | 2.6 | ±0.2 | 19 | 0.3 | ±0.1 | 178 | 5.7 | ±0.8 | 142 | 20.3 | ±3.3 |
| Urinary Bladder | 618 | 4.9 | ±0.3 | 5 | * | 193 | 6.1 | ±0.9 | 420 | 60.0 | ±5.7 | |
| Kidney and Renal Pelvis | 444 | 3.3 | ±0.3 | 12 | 0.2 | ±0.1 | 222 | 7.1 | ±0.9 | 210 | 30.0 | ±4.0 |
| Other Urinary | 33 | 0.2 | ±0.1 | - | - | 14 | 0.4 | ±0.2 | 19 | 2.7 | ±1.2 | |
| Brain & Other Central Nervous System |
626 | 4.9 | ±0.4 | 96 | 1.5 | ±0.3 | 375 | 11.9 | ±1.2 | 155 | 22.2 | ±3.5 |
| Lymphomas | 802 | 6.2 | ±0.4 | 29 | 0.5 | ±0.2 | 336 | 10.7 | ±1.1 | 437 | 62.5 | ±5.8 |
| Hodgkin Lymphoma | 29 | 0.2 | ±0.1 | 2 | * | 15 | 0.5 | ±0.2 | 12 | 1.7 | ±1.0 | |
| Non-Hodgkin Lymphoma |
773 | 6.0 | ±0.4 | 27 | 0.4 | ±0.2 | 321 | 10.2 | ±1.1 | 425 | 60.7 | ±5.7 |
| Multiple Myeloma | 440 | 3.4 | ±0.3 | 17 | 0.3 | ±0.1 | 185 | 5.9 | ±0.8 | 238 | 34.0 | ±4.3 |
| Leukemias | 822 | 6.5 | ±0.4 | 41 | 0.7 | ±0.2 | 310 | 9.9 | ±1.1 | 471 | 67.3 | ±6.0 |
| All Other | 1,854 | 14.2 | ±0.6 | 65 | 1.0 | ±0.2 | 864 | 27.5 | ±1.8 | 925 | 132.2 | ±8.4 |
| Total | 21,118 | 160.3 | ±2.0 | 871 | 14.0 | ±0.9 | 10,954 | 348.4 | ±6.2 | 9,293 | 1,328.1 | ±22.8 |
| Notes: | Age-Specific Rates are per 100,000 population
in a specific age group. Age-Adjusted Rates are per 100,000 population. Age-adjusted rates are computed by the direct method, using as the standard population the age distribution of the total population of the United States for the year 2000. Adding and subtracting the number shown after the ± symbol from the rate creates a confidence interval indicating that the true rate lies between the lower and upper bounds of this interval with 95 % statistical confidence. *: A rate is not calculated when there are fewer than 20 total events, or fewer than 6 events in an age category, because the width of the confidence interval would negate any usefulness for comparative purposes. COVID-19 Pandemic: In 2020, the highly publicized impact of the COVID-19 pandemic on health services and the consequential delays and reductions in cancer screening and diagnosis led to a decline in the 2020 incidence rates for most cancer sites. Because 2020 was a temporary, anomalous year, it can bias estimates such as cancer incidence trends. |
| Source: | 2020 Michigan Resident Death File, Division for Vital Records & Health Statistics, Michigan Department of Health & Human Services. |
| Last Updated: | April 13, 2023 |